UroGen Pharma (URGN) Short Interest Ratio & Short Volume → 25% of Americans Are In Grave Danger (From Banyan Hill Publishing) (Ad) Free URGN Stock Alerts $13.21 +0.02 (+0.15%) (As of 06/7/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends UroGen Pharma Short Interest DataCurrent Short Interest4,470,000 sharesPrevious Short Interest4,430,000 sharesChange Vs. Previous Month+0.90%Dollar Volume Sold Short$61.60 millionShort Interest Ratio13.7 Days to CoverLast Record DateMay 15, 2024Outstanding Shares23,450,000 sharesPercentage of Shares Shorted19.06%Today's Trading Volume159,493 sharesAverage Trading Volume291,827 sharesToday's Volume Vs. Average55% Short Selling UroGen Pharma ? Sign up to receive the latest short interest report for UroGen Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartURGN Short Interest Over TimeURGN Days to Cover Over TimeURGN Percentage of Float Shorted Over Time Ad Banyan Hill Publishing25% of Americans Are In Grave DangerAccording to this White House briefing … AI will replace up to 300 million jobs. That would amount to 25% of ALL jobs — worldwide But this isn’t a one-sided story…Click here for details. UroGen Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20244,470,000 shares $61.60 million +0.9%N/A13.7 $13.78 4/30/20244,430,000 shares $61.22 million +5.5%N/A12.7 $13.82 4/15/20244,200,000 shares $63.42 million +0.2%N/A11.5 $15.10 3/31/20244,190,000 shares $62.85 million -1.4%N/A12.6 $15.00 3/15/20244,250,000 shares $61.46 million +8.1%N/A12.4 $14.46 2/29/20243,930,000 shares $72.04 million -2.0%N/A12.7 $18.33 Get the Latest News and Ratings for URGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. 2/15/20244,010,000 shares $75.39 million +23.0%N/A13.2 $18.80 1/31/20243,260,000 shares $51.18 million -3.8%N/A11 $15.70 1/15/20243,390,000 shares $49.46 million -4.5%N/A12.9 $14.59 12/31/20233,550,000 shares $53.25 million +15.6%N/A13.5 $15.00 12/15/20233,070,000 shares $46.05 million +5.1%N/A11.3 $15.00 11/30/20232,920,000 shares $38.51 million +3.2%N/A12.4 $13.19 11/15/20232,830,000 shares $32.77 million +23.6%N/A11.4 $11.58 10/31/20232,290,000 shares $25.67 million +39.6%N/A7.9 $11.21 10/15/20231,640,000 shares $21.48 million +14.7%N/A2.6 $13.10 9/30/20231,430,000 shares $20.03 million +10.9%N/A2.3 $14.01 9/15/20231,290,000 shares $20.52 million -8.5%N/A2.1 $15.91 8/31/20231,410,000 shares $24.65 million -15.1%N/A2.2 $17.48 8/15/20231,660,000 shares $37.12 million +5.7%N/A2.7 $22.36 7/31/20231,570,000 shares $34.01 million +55.5%N/A2.8 $21.66 7/15/20231,010,000 shares $9.28 million +11.1%5.1%4 $9.19 6/30/2023909,100 shares $9.41 million +38.5%4.6%3.8 $10.35 6/15/2023656,300 shares $8.07 million -23.0%3.3%2.7 $12.29 5/31/2023852,100 shares $8.44 million -9.8%4.3%4.6 $9.90 5/15/2023944,700 shares $11.16 million +29.3%4.8%5.4 $11.81 4/30/2023730,500 shares $8.47 million -1.8%3.7%4.3 $11.59 4/15/2023743,700 shares $7.16 million +16.3%3.8%5.8 $9.63 3/31/2023639,500 shares $5.91 million +2.3%3.3%5.6 $9.24 3/15/2023625,300 shares $6.02 million +5.5%3.3%6.3 $9.63 2/28/2023592,900 shares $6.11 million +2.8%3.1%6.7 $10.30 2/15/2023576,700 shares $5.29 million +1.2%3.0%6.4 $9.17 1/31/2023569,700 shares $5.92 million +0.0%3.0%6.6 $10.39 1/15/2023569,600 shares $4.88 million -15.2%2.9%7.7 $8.56 12/30/2022671,700 shares $5.96 million -0.2%3.5%8.9 $8.87 12/15/2022673,000 shares $5.32 million +0.1%3.5%10.2 $7.91 11/30/2022672,600 shares $5.76 million -1.0%3.5%10.3 $8.57 11/15/2022679,700 shares $6.17 million -9.5%3.5%10.5 $9.08 10/31/2022751,100 shares $8.90 million -31.7%3.9%13 $11.85 10/15/20221,100,000 shares $12.65 million -20.3%5.8%19.5 $11.50 9/30/20221,380,000 shares $11.48 million -3.5%7.2%25.6 $8.32Was the Great Financial Crisis fun? (Ad)The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, was terrible! The majority of market indexes lost over 50% of their value. Almost every day, traders would look at their trading accounts and just see a sea of red.Get those kind of results during the Great Financial Crisis, without having to study more 9/15/20221,430,000 shares $13.46 million +1.4%7.5%15 $9.41 8/31/20221,410,000 shares $10.50 million -3.4%7.3%13 $7.45 8/15/20221,460,000 shares $12.64 million -0.7%7.6%10.3 $8.66 7/31/20221,470,000 shares $11.52 million -3.3%7.7%8.9 $7.84 7/15/20221,520,000 shares $13.77 million -10.6%7.9%8.4 $9.06 6/30/20221,700,000 shares $13.92 million -22.0%8.9%8.7 $8.19 6/15/20222,180,000 shares $14.72 million -10.7%11.4%10.6 $6.75 5/31/20222,440,000 shares $12.98 million +3.4%12.7%14.6 $5.32 5/15/20222,360,000 shares $14.04 million +3.5%12.3%15.8 $5.95 4/30/20222,280,000 shares $16.10 million +10.1%11.9%17 $7.06 4/15/20222,070,000 shares $16.21 million +4.6%10.8%15.7 $7.83 3/31/20221,980,000 shares $17.25 million -10.0%10.4%14.9 $8.71 3/15/20222,200,000 shares $18.55 million -0.5%11.6%16.7 $8.43 2/28/20222,210,000 shares $13.26 million +11.1%11.7%15.8 $6.00 2/15/20221,990,000 shares $14.23 million No Change10.5%14.5 $7.15 1/31/20221,990,000 shares $15.36 million +7.6%10.5%12.8 $7.72 1/15/20221,850,000 shares $15.71 million +2.2%9.8%12.2 $8.49 12/31/20211,810,000 shares $17.21 million -4.2%9.5%13.8 $9.51 12/15/20211,890,000 shares $19.18 million +3.9%9.9%16.3 $10.15 11/30/20211,820,000 shares $22.00 million +11.0%9.6%17.9 $12.09 11/15/20211,640,000 shares $24.17 million -6.3%8.6%16.8 $14.74 10/29/20211,750,000 shares $30.10 million -0.6%9.2%22.4 $17.20 10/15/20211,760,000 shares $29.96 million -4.9%9.3%20.8 $17.02 9/30/20211,850,000 shares $31.12 million -10.2%9.8%16.5 $16.82 9/15/20212,060,000 shares $31.37 million -6.8%10.9%16.1 $15.23 8/31/20212,210,000 shares $38.94 million -0.5%11.7%16.3 $17.62 8/13/20212,220,000 shares $33.59 million +7.8%11.7%16.1 $15.13 7/30/20212,060,000 shares $31.93 million -1.4%10.9%13.8 $15.50 7/15/20212,090,000 shares $32.19 million -1.9%11.1%14.8 $15.40 6/30/20212,130,000 shares $32.53 million -6.2%11.3%16.1 $15.27 6/15/20212,270,000 shares $38.79 million -7.4%12.0%17.4 $17.09 5/28/20212,450,000 shares $43.17 million +5.2%13.0%16.2 $17.62 5/14/20212,330,000 shares $35.84 million -0.4%12.3%13 $15.38 4/30/20212,340,000 shares $47.20 million -1.3%12.4%12.9 $20.17 4/15/20212,370,000 shares $41.78 million +1.7%12.5%12 $17.63 3/31/20212,330,000 shares $43.15 million -4.9%12.3%11.2 $18.52 3/15/20212,450,000 shares $48.00 million -11.2%12.9%11.1 $19.59 2/26/20212,760,000 shares $55.89 million +1.5%14.7%13.6 $20.25 2/12/20212,720,000 shares $70.94 million +3.8%14.5%14.8 $26.08 1/29/20212,620,000 shares $58.61 million -0.8%13.9%14.6 $22.37 1/15/20212,640,000 shares $55.26 million -1.9%14.0%15.3 $20.93 12/31/20202,690,000 shares $48.66 million +8.9%14.3%17.4 $18.09 12/15/20202,470,000 shares $45.97 million -9.5%13.1%17.9 $18.61 11/30/20202,730,000 shares $55.97 million +2.6%14.4%21.2 $20.50 10/30/20203,010,000 shares $69.20 million -3.8%16.0%20.1 $22.99 10/15/20203,130,000 shares $70.77 million -1.6%16.6%20.5 $22.61 9/30/20203,180,000 shares $61.34 million -0.6%16.9%20.5 $19.29 9/15/20203,200,000 shares $70.43 million +2.9%17.0%20.1 $22.01 8/31/20203,110,000 shares $78.03 million -0.6%16.5%19.7 $25.09 8/14/20203,130,000 shares $71.83 million +2.3%16.6%21 $22.95Was the Great Financial Crisis fun? (Ad)The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, was terrible! The majority of market indexes lost over 50% of their value. Almost every day, traders would look at their trading accounts and just see a sea of red.Get those kind of results during the Great Financial Crisis, without having to study more 7/31/20203,060,000 shares $67.60 million +2.3%17.0%18.9 $22.09 7/15/20202,990,000 shares $70.89 million +5.7%16.7%15.8 $23.71 6/30/20202,830,000 shares $73.92 million +5.2%15.9%11.7 $26.12 6/15/20202,690,000 shares $71.55 million -2.9%15.1%10.6 $26.60 5/29/20202,770,000 shares $66.48 million +1.8%16.1%10 $24.00 5/15/20202,720,000 shares $67.05 million +3.0%15.8%9.9 $24.65 4/30/20202,640,000 shares $64.34 million +3.1%14.2%10.2 $24.37 4/15/20202,560,000 shares $53.86 million +10.3%14.9%11 $21.04 3/31/20202,320,000 shares $41.39 million +9.1%13.5%11.9 $17.84 3/13/20202,126,500 shares $45.29 million -11.8%13.4%9.7 $21.30 2/28/20202,410,000 shares $39.09 million +1.3%15.1%14.7 $16.22 2/14/20202,380,000 shares $65.83 million -0.8%14.0%14.8 $27.66 1/31/20202,400,000 shares $68.26 million +13.2%14.1%14 $28.44 1/15/20202,120,000 shares $63.54 million +17.8%12.5%11.8 $29.97 12/31/20191,800,000 shares $54.81 million -24.4%10.6%11 $30.45 URGN Short Interest - Frequently Asked Questions What is UroGen Pharma's current short interest? Short interest is the volume of UroGen Pharma shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 4,470,000 shares of URGN short. Learn More on UroGen Pharma's current short interest. What is a good short interest ratio for UroGen Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. URGN shares currently have a short interest ratio of 14.0. Learn More on UroGen Pharma's short interest ratio. Is UroGen Pharma's short interest increasing or decreasing? UroGen Pharma saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,470,000 shares, an increase of 0.9% from the previous total of 4,430,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does UroGen Pharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to UroGen Pharma: Akebia Therapeutics, Inc. (5.58%), Puma Biotechnology, Inc. (8.63%), RAPT Therapeutics, Inc. (8.91%), Marinus Pharmaceuticals, Inc. (8.90%), Mirum Pharmaceuticals, Inc. (18.69%), Prothena Co. plc (12.11%), Calliditas Therapeutics AB (publ) (0.03%), Day One Biopharmaceuticals, Inc. (17.50%), Arcturus Therapeutics Holdings Inc. (16.81%), AbCellera Biologics Inc. (9.58%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short UroGen Pharma stock? Short selling URGN is an investing strategy that aims to generate trading profit from UroGen Pharma as its price is falling. URGN shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against UroGen Pharma? A short squeeze for UroGen Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of URGN, which in turn drives the price of the stock up even further. How often is UroGen Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including URGN, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Akebia Therapeutics Short Interest Data Puma Biotechnology Short Interest Data RAPT Therapeutics Short Interest Data Marinus Pharmaceuticals Short Interest Data Mirum Pharmaceuticals Short Interest Data Prothena Short Interest Data Calliditas Therapeutics AB (publ) Short Interest Data Day One Biopharmaceuticals Short Interest Data Arcturus Therapeutics Short Interest Data AbCellera Biologics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:URGN) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredTime is Running Out - June 25th Deadline Approaching!If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.